🟢 Strong Evidence
The World Health Organization (WHO) has added the first molecular diagnostic test for Bundibugyo virus (BDBV) to its Emergency Use Listing (EUL), a regulatory mechanism designed to accelerate access to quality-assured health products during public health crises. The test identifies viral genetic material in blood samples, enabling rapid and accurate confirmation of infection. This decision comes as countries respond to the largest recorded outbreak of BDBV, following WHO Director-General Dr Tedros Adhanom Ghebreyesus’s declaration on 17 May 2026 of a public health emergency of international concern over the outbreak in the Democratic Republic of the Congo, with cases reported in Uganda.
Key takeaways
- WHO’s Emergency Use Listing now includes the first quality-assured diagnostic test for Bundibugyo virus, enabling rapid case detection and outbreak response
- The test detects viral genetic material through molecular analysis of blood samples, meeting international standards for quality, safety, and performance
- Approval came less than two weeks after WHO’s emergency call for manufacturers, accelerating access to diagnostic tools during the largest recorded BDBV outbreak
WHO Emergency Use Listing Process Timeline for BDBV Diagnostics
From emergency declaration to diagnostic test approval, 2026
Source: WHO Emergency Response Timeline, 2026 | Georgian Medical Journal News
Rapid deployment of quality-assured diagnostics
The WHO Emergency Use Listing procedure evaluates diagnostic tests based on evidence of quality, safety, and performance while ensuring alignment with international standards and addressing the needs of low- and middle-income countries. The EUL mechanism supports UN procurement agencies and governments in making informed decisions about product procurement during public health emergencies, accelerating access without compromising safety oversight.
Dr Yukiko Nakatani, WHO Assistant Director-General for Health Systems, Access and Data, emphasised the critical timing: “During a fast-moving outbreak, timely access to quality-assured diagnostic tests can make a critical difference in containing transmission.” The approval reflects WHO’s commitment to supporting countries in responding to the outbreak through trusted diagnostic tools, enabling early case detection, timely clinical care, disease surveillance, and effective outbreak containment.
Context: the Bundibugyo virus outbreak
Bundibugyo virus is one of six known species within the Ebola genus. The current outbreak, centred in the Democratic Republic of the Congo with cases also reported in Uganda, represents the largest recorded epidemic of BDBV to date. Rapid diagnostic capacity is essential for identifying cases early, implementing infection control measures, and preventing further transmission.
Access to reliable, standardised diagnostic tests is a cornerstone of effective outbreak response. The EUL approval removes procurement barriers for countries responding to the emergency, enabling rapid distribution through UN supply chains and national health systems. Global health emergencies increasingly depend on transparent, evidence-based approval pathways that balance speed with safety assurance.
Implications for outbreak containment and future preparedness
The availability of a WHO-validated diagnostic test strengthens the technical foundation for outbreak response. Confirmed cases can be identified rapidly, contacts traced systematically, and transmission prevented through isolation and treatment support. Clinical decision-making improves when diagnostic certainty is achieved early in infection, before symptom onset and peak viral loads.
This approval also signals WHO’s regulatory capacity to respond to emerging threats with evidence-based urgency. As novel pathogens emerge, the EUL framework offers a blueprint for scaling diagnostic access while maintaining quality oversight—a model that strengthens global biosecurity and pandemic preparedness.
The first quality-assured molecular diagnostic test for Bundibugyo virus was added to the WHO Emergency Use Listing to enable rapid case detection and outbreak response during the largest recorded BDBV epidemic.
— WHO Emergency Response, 2 July 2026
What this means
Frequently asked questions
What is the WHO Emergency Use Listing?
The EUL is a WHO regulatory mechanism that rapidly assesses and approves essential health products—including diagnostics, vaccines, and medicines—during public health emergencies. Products must meet minimum standards for quality, safety, and performance, ensuring that speed does not compromise reliability. The listing supports UN procurement agencies and governments in sourcing trusted products for outbreak response.
How does this diagnostic test work?
The approved test uses molecular analysis to detect Bundibugyo virus genetic material (RNA) in blood samples. This approach, known as reverse transcription polymerase chain reaction (RT-PCR), is highly sensitive and specific, confirming infection rapidly—typically within hours—making it ideal for outbreak settings where early case identification is critical.
Why is rapid diagnostic access crucial during an Ebola outbreak?
Early diagnosis enables prompt isolation of confirmed cases, preventing transmission to healthcare workers and contacts. Rapid diagnostic capacity also supports epidemiological investigation, identifying transmission chains and guiding outbreak containment strategies. Without reliable diagnostics, suspected cases may be managed in isolation pending confirmation, straining healthcare resources and delaying treatment for uninfected individuals.
The approval of this first diagnostic test represents a critical step in the international response to the Bundibugyo virus outbreak. As outbreak investigations continue and case numbers are monitored, the availability of WHO-validated diagnostics will enable countries to respond with greater speed and precision. Continued focus on strengthening laboratory capacity, supply chain resilience, and health system preparedness in affected regions will be essential for containing transmission and protecting vulnerable populations.
Source: WHO adds first diagnostic test for Ebola Bundibugyo virus to its Emergency Use Listing
Was this article helpful?
Related Coverage
